CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended				63 Months Ended
	Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2012
Revenue	$ 0		$ 0		$ 0
Operating expense
General & administrative	986,097	[1]	1,224,813	[1]	7,059,463	[1]
Total operating expense	2,582,679		2,365,615		12,448,679
Net operating loss	(2,582,679)		(2,365,615)		(12,448,679)
Other income
Interest income	779		2,907		77,091
Other income	0		0		244,479
Other expense	(637)		(636)		(4,174)
Total Other Income	142		2,271		317,396
Net Loss Before Income Taxes	(2,582,537)		(2,363,344)		(12,131,283)
Income tax expense	0		0		0
Net Loss	(2,582,537)		(2,363,344)		(12,131,283)
Loss per share
Net loss per share, basic and diluted	$ (0.04)		$ (0.04)		$ (0.26)
Basic and diluted weighted average number of common shares outstanding	59,317,779		53,844,195		46,045,124
All Other
Operating expense
Research and development	1,132,712	[2]	596,802	[2]	4,325,596	[2]
MD Anderson for License
Operating expense
Research and development	$ 463,870	[3]	$ 544,000	[3]	$ 1,063,620	[3]

[1] General & administrative expense includes stock option expense of $9,740 and $316,820 for the years ending 12/31/2012 and 12/31/2011, respectively; and for the period from inception through 12/31/2012, $2,590,753 for stock option and warrant expense and $318,500 in stock for services.

[2] Research and development expense includes stock option expense of $53,645 and $66,098 for the years ending 12/31/2012 and 12/31/2011, respectively; and $422,999 for the period from inception through 12/31/2012. Research and development expense also includes amortization expense of $185,271 and $211,709 for the years ending 12/31/2012 and 12/31/2011, respectively; and $976,734 for the period from inception through 12/31/2012.

[3] Includes $345,000 technology impairment charge for the year ending 12/31/2012 and $345,000 technology impairment for the year ending 12/31/2011; and technology impairment of $690,000 for the period from inception through 12/31/2012.